License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	$ 238,988	$ 211,237	$ 470,483	$ 400,062
Development Milestone and Upfront Fee Recognized as Research and Development Expense	7,600	8,800	8,100	8,800
Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for option exercise			221,300
Research, option and milestone expense		6,000		6,000
No additional research milestone payments			0
Collaborative Arrangement | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent research milestone payments			39,800
Development Milestone and Settlement Upfront Fee Recognized as Research and Development Expense	3,200,000		3,200,000
Collaborative Arrangement | Research and Development Expense [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Up-front and development milestone expenses	7,500		7,500
Collaborative Arrangement | Roche Holding A.G. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	22,300	22,300	44,300	44,300
Deferred Revenue	530,000		530,000
Deferred Revenue, Current	45,000		45,000
Deferred Revenue Separate Material Options Right	485,000	485,000	485,000	485,000
Research and development expense	28,200	$ 26,400	48,500	$ 44,100
Collaboration Receivable	28,600		28,600
Nationwide License Agreement [Member] | Nationwide Childrens Hospital [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sales milestone payment recorded as an in-license right	10,000		10,000
Carrying value	$ 10,000		$ 10,000